Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register
14/08/2023
Molina J, Sanchez-Alonso F, Bohorquez C, Diaz-Torne C, Perez-Garcia C, Blanco-Madrigal J, Vela-Casampere P, Älvaro-Gracia J, Castrejon I
ACR 2022
Molina J, Sanchez-Alonso F, Bohorquez C, Diaz-Torne C, Perez-Garcia C, Blanco-Madrigal J, Vela-Casampere P, Älvaro-Gracia J, Castrejon I. Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/cancer-risk-with-biologic-and-targeted-synthetic-dmards-in-patients-with-rheumatic-diseases-and-previous-malignancy-results-from-the-biobadaser-register/
https://acrabstracts.org/abstract/cancer-risk-with-biologic-and-targeted-synthetic-dmards-in-patients-with-rheumatic-diseases-and-previous-malignancy-results-from-the-biobadaser-register/